|
Group
|
TAA(×103μm2)
|
LA(×103μm2)
|
CSA(×103μm2)
|
CSA/TAA(%)
|
AR(μm)
|
Lumen(μm)
|
Media(μm)
|
M/L(%)
|
|---|
|
Control
|
424.5 ± 81.2
|
271.7 ± 66.6
|
152.8 ± 17.9
|
36.0 ± 22.0
|
366.4 ± 33.8
|
292.5 ± 33.9
|
73.9 ± 4.6
|
25.5 ± 3.0
|
|
Model
|
686.8 ± 162.3**
|
426.4 ± 97.1**
|
260.3 ± 73.1**
|
27.9 ± 45.0
|
464.8 ± 56.7**
|
366.3 ± 44.3**
|
98.5 ± 17.6**
|
27.0 ± 3.8
|
|
L-NAME+AqE
|
496.6 ± 81.5#
|
319.0 ± 59.6#
|
177.6 ± 22.0#
|
35.8 ± 27.0
|
396.5 ± 33.5#
|
317.5 ± 30.7
|
78.9 ± 2.9#
|
25.0 ± 1.7
|
|
L-NAME+XJEK
|
499.9 ± 65.2#
|
327.1 ± 59.5
|
172.9 ± 22.2#
|
34.6 ± 34.0
|
398.3 ± 26.7#
|
321.6 ± 29.4
|
76.6 ± 9.6#
|
24.1 ± 4.2
|
|
L-NAME+Fosinopril
|
445.1 ± 220.2#
|
292.5 ± 148.9#
|
153.2 ± 726.7#
|
34.4 ± 33.0
|
336.3 ± 159.0#
|
272.1 ± 129.2#
|
64.7 ± 30.0#
|
22.1 ± 6.5
|
- TAA total aorta area, LA lumen area, CSA cross-sectional area, AR aorta radius. The vascular remodeling of the upper thoracic aorta exposed to L-NAME was observed at the end of 8th week, which could be prevented by treatment with AqE for the last 4 weeks, as well as with two positive drugs, XJEK and fosinopril. Data are expressed as mean ± SD, n = 10. **P < 0.01 vs control; #P < 0.05 vs model
